NR2E3 and retinitis pigmentosa: This dose was selected based on the work of Naessens et al.,21 who showed a 50%–70% decrease in target transcripts in an overexpression-based cell model to identified candidate AONs for the future treatment of NR2E3-associated retinitis pigmentosa.